ACR 2.82% 6.9¢ acrux limited

Ann: Acrux announces commercial agreement with Padagis, page-15

  1. 5,931 Posts.
    lightbulb Created with Sketch. 50
    I must be slipping!! Have just noticed that Dash Pharma was bought out and is now a holly owned subsidiary of Natco Pharma, effective 1st Jan 2022. Sale price was US$18 million. That's good in one way as Natco is listed on the NY Stock Exchange. So I've had a look at Natco's Jan to March 2022 QTR Financials, but unfortunatly there is no breakdown of revenue streams from subsidiary's nor a break down individual drug products. So I have sent a request to Natco as to where I can obtain this information. Being a public company it should be readily available. I'll keep you all posted. So with all that happens during a takeover I can only hope that the Dash Pharma Team were not distracted too much when it comes to our testosterone interests.
 
watchlist Created with Sketch. Add ACR (ASX) to my watchlist
(20min delay)
Last
6.9¢
Change
-0.002(2.82%)
Mkt cap ! $20.05M
Open High Low Value Volume
7.5¢ 7.5¢ 6.9¢ $31.16K 433.1K

Buyers (Bids)

No. Vol. Price($)
1 54422 6.9¢
 

Sellers (Offers)

Price($) Vol. No.
7.2¢ 147301 2
View Market Depth
Last trade - 15.53pm 28/06/2024 (20 minute delay) ?
ACR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.